Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion
Gilead Sciences is buying CymaBay Therapeutics for $4.3 billion, giving Gilead access to CymaBay's lead treatment for liver disease.
( 1
min )